


RealRate

PHARMACEUTICAL 2018

Myovant Sciences Ltd. Rank 64 of 342







RealRate

Myovant Sciences Ltd. Rank 64 of 342

The relative strengths and weaknesses of Myovant Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Myovant Sciences Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 125% points. The greatest weakness of Myovant Sciences Ltd. is the variable Other Revenues, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 200%, being 154% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	184,164
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,337
Liabilities, Non-Current	0
Other Assets	208
Other Compr. Net Income	140
Other Expenses	27,583
Other Liabilities	165
Other Net Income	0
Other Revenues	0
Property and Equipment	906
Research and Development	43,500
Selling, General and Administrative Expense	12,357

Output Variable	Value in 1000 USD
Assets	185,278
Liabilities	18,502
Expenses	83,440
Revenues	0
Stockholders Equity	166,776
Net Income	-83,440
Comprehensive Net Income	-83,370
Economic Capital Ratio	200%

